Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. | Front Oncol;11: 624780, 2021. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.

Karimi, Amirali; Alilou, Sanam; Mirzaei, Hamid Reza.

Affiliation

Karimi A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Alilou S; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mirzaei HR; Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Front Oncol ; 11: 624780, 2021.

Article in En | MEDLINE | ID: mdl-33767992

Key words

Anti-CTLA4 antibody; CTLA4; adverse events; cancer immunotherapy; ipilimumab

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Front Oncol Year: 2021 Document type: Article Affiliation country: Irán Country of publication: Suiza

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Front Oncol Year: 2021 Document type: Article Affiliation country: Irán Country of publication: Suiza